Litmus email source
Copy source
<!DOCTYPE html> <html xmlns="http://www.w3.org/1999/xhtml" xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office"> <head> <title>Novo Nordisk</title> <meta http-equiv="Content-Type" content="text/html; charset=utf-8"> <meta name="viewport" content="width=device-width"> <!--[if gte mso 9]><xml> <o:OfficeDocumentSettings> <o:AllowPNG/> <o:PixelsPerInch>96</o:PixelsPerInch> </o:OfficeDocumentSettings> </xml><![endif]--> <!--[if (gte mso 15)|(IE)]> <style type="text/css"> table { border-collapse: collapse; border-spacing: 0; mso-line-height-rule: exactly; mso-margin-bottom-alt: 0; mso-margin-top-alt: 0; mso-table-lspace: 0pt; mso-table-rspace: 0pt;} td {mso-hyphenate: none;} </style> <![endif]--> <!--[if gte mso 9]> <style> sup, sub { font-size: 100% !important; } </style> <![endif]--> <style type="text/css"> @media screen { @font-face { font-family: 'Noto Sans'; font-style: italic; font-weight: 400; font-display: fallback; src: local('Noto Sans Italic'), local('NotoSans-Italic'), url('https://fonts.gstatic.com/s/notosans/v9/o-0OIpQlx3QUlC5A4PNr4ARCQ_mu72Bi.woff2') format('woff2'); unicode-range: U+0000-00FF, U+0131, U+0152-0153, U+02BB-02BC, U+02C6, U+02DA, U+02DC, U+2000-206F, U+2074, U+20AC, U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD; } @font-face { font-family: 'Noto Sans'; font-style: italic; font-weight: 700; font-display: fallback; src: local('Noto Sans Bold Italic'), local('NotoSans-BoldItalic'), url('https://fonts.gstatic.com/s/notosans/v9/o-0TIpQlx3QUlC5A4PNr4Az5ZuyDzW1IPrie.woff2') format('woff2'); unicode-range: U+0000-00FF, U+0131, U+0152-0153, U+02BB-02BC, U+02C6, U+02DA, U+02DC, U+2000-206F, U+2074, U+20AC, U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD; } @font-face { font-family: 'Noto Sans'; font-style: normal; font-weight: 400; font-display: fallback; src: local('Noto Sans'), local('NotoSans'), url('https://fonts.gstatic.com/s/notosans/v9/o-0IIpQlx3QUlC5A4PNr5TRASf6M7Q.woff2') format('woff2'); unicode-range: U+0000-00FF, U+0131, U+0152-0153, U+02BB-02BC, U+02C6, U+02DA, U+02DC, U+2000-206F, U+2074, U+20AC, U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD; } @font-face { font-family: 'Noto Sans'; font-style: normal; font-weight: 700; font-display: fallback; src: local('Noto Sans Bold'), local('NotoSans-Bold'), url('https://fonts.gstatic.com/s/notosans/v9/o-0NIpQlx3QUlC5A4PNjXhFVZNyBx2pqPA.woff2') format('woff2'); unicode-range: U+0000-00FF, U+0131, U+0152-0153, U+02BB-02BC, U+02C6, U+02DA, U+02DC, U+2000-206F, U+2074, U+20AC, U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD; } } #outlook a { padding: 0; } .ReadMsgBody { width: 100%; } .ExternalClass { width: 100%; } .ExternalClass, .ExternalClass p, .ExternalClass span, .ExternalClass font, .ExternalClass td, .ExternalClass div { line-height: 100%; } body, table, td, a { -webkit-text-size-adjust: 100%; -ms-text-size-adjust: 100%; } table, td { mso-table-lspace: 0pt; mso-table-rspace: 0pt; } img { -ms-interpolation-mode: bicubic; } body { margin: 0; padding: 0; } img { border: 0; height: auto; line-height: 100%; outline: none; text-decoration: none; } table { border-collapse: collapse !important; } body { height: 100% !important; margin: 0 auto !important; padding: 0; width: 100% !important; } .default-blue-text a { color: #001965; text-decoration: none; } .default-blue-link-text a { color: #025edc; text-decoration: underline; } @media screen and (max-width: 670px) { img.img-responsive { width: 100% !important; height: auto !important; } } @media screen and (max-width: 670px) { .max-width-mobile-240 { max-width: 240px !important; } } @media screen and (max-width: 670px) { table.mobile-hide, td.mobile-hide, img.mobile-hide, .mobile-hide { display: none !important; } } @media screen and (max-width: 670px) { div.mobile-only-content { display: block !important; max-height: none !important; max-width: 100% !important; height: auto !important; width: auto !important; visibility: visible !important; } } @media screen and (max-width: 670px) { th.responsive-th { display: block !important; width: 100% !important; } } @media screen and (max-width: 670px) { .email-container { max-width: 610px !important; width: 100% !important; } } @media screen and (max-width: 670px) { .col-80 { width: 100% !important; } .col-290 { width: 100% !important; } .col-295 { width: 100% !important; } .col-335 { width: 100% !important; } } @media screen and (max-width: 670px) { .mfs-11 { font-family: "Noto Sans", Apis, Arial, Helvetica, sans-serif; font-weight: normal; color: #001965; font-size: 11px !important; line-height: 1.4; } } @media screen and (max-width: 670px) { .mfs-16 { font-family: "Noto Sans", Apis, Arial, Helvetica, sans-serif; font-weight: normal; color: #001965; font-size: 16px !important; line-height: 1.4; } } @media screen and (max-width: 670px) { .mfs-24 { font-family: "Noto Sans", Apis, Arial, Helvetica, sans-serif; font-weight: normal; color: #001965; font-size: 24px !important; line-height: 1.2; } } @media screen and (max-width: 670px) { .mlh-22 { line-height: 22px !important; } } @media screen and (max-width: 670px) { .mlh-32 { line-height: 32px !important; } } @media screen and (max-width: 670px) { .text-center { text-align: center !important; } } @media screen and (max-width: 670px) { .mpt-12 { padding-top: 12px !important; } .mpb-15 { padding-bottom: 15px !important; } .mpb-16 { padding-bottom: 16px !important; } .mpb-20 { padding-bottom: 20px !important; } .mpb-24 { padding-bottom: 24px !important; } .mpb-32 { padding-bottom: 32px !important; } .mpb-44 { padding-bottom: 44px !important; } } @media screen and (max-width: 670px) { .email-gutter { padding-right: 20px !important; padding-left: 20px !important; } } @media screen and (max-width: 670px) { .email-gutter-desktop-only { padding-right: 0 !important; padding-left: 0 !important; } } @media screen and (max-width: 670px) { .email-gutter-desktop-only-20 { padding-right: 0 !important; padding-left: 0 !important; } } @media screen and (max-width: 670px) { .email-gutter-mobile-only { padding-right: 20px !important; padding-left: 20px !important; } } @media screen and (max-width: 670px) { .email-gutter-15 { padding-right: 20px !important; padding-left: 20px !important; } .email-gutter-40 { padding-right: 20px !important; padding-left: 20px !important; } } @media screen and (max-width: 670px) { .email-gutter-mobile-10 { padding-right: 10px !important; padding-left: 10px !important; } } </style> </head> <body style="background-color: #f3f3f4;"> <center style="width: 100%"> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="background-color: #f3f3f4;"> <tr> <td align="center"> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter-desktop-only" style="background-color: #f3f3f4; padding-left: 30px; padding-right: 30px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="border-bottom: 1px solid #E5E3E6;"> <tr> <td valign="top" class="email-gutter-15" style="padding-bottom: 10px; padding-left: 15px; padding-right: 15px; padding-top: 10px;"> <table cellpadding="0" cellspacing="0" border="0" align="left" width="100%"> <tr> <td align="left" valign="top"> <!-- Preheader text --> <div style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 12px;">Choose the bypassing agent your hospital can count on for the most indications.</div> <!-- Preheader filler spaces --> <div style="display: none; max-height: 0; max-width: 0; width: 0; visibility: hidden; overflow: hidden; font-size: 1px; line-height: 0; mso-hide: all;">  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ </div> </td> <td align="right" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 1.4; width: 100px;"><a href="#" target="_blank" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">View online</a></td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td valign="top"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="center" class="email-gutter-mobile-10 mpb-16" style="padding-bottom: 8px; padding-top: 12px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="center" valign="middle" class="mfs-11" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 1.4; padding: 0 5px 0 0;"><a href="https://www.novomedlink.com/rare-bleeding-disorders/products/treatments/novosevenrt.html?showIsi=true" target="_blank" style="color: #ff0000; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">Important Safety Information</a></td> <td align="center" style="color: #4a4a4a; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 1.4;"> | </td> <td align="center" valign="middle" class="mfs-11" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 1.4; padding: 0 0 0 5px;"><a href="https://www.novo-pi.com/novosevenrt.pdf" target="_blank" style="color: #ff0000; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">Prescribing Information</a></td> </tr> </table> </td> </tr> <tr> <td align="center" class="email-gutter" style="padding-left: 30px; padding-right: 30px;"><a href="https://www.novomedlink.com/rare-bleeding-disorders/products/treatments/novosevenrt.html" target="_blank" style="color: #ff0000; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;"><img src="https://emails.hemo.novo.cglife.dev/emails/n7-hcp-pharmacy-cpd/images/novoseven-logo.png" width="320" height="90" border="0" alt="NovoSeven RT Coagulation Factor VIIa (Recombinant) logo." class="img-responsive max-width-mobile-240" style="display: inline-block;"></a></td> </tr> <tr> <td align="center" class="mpt-12 email-gutter-40" style="padding-bottom: 16px; padding-left: 40px; padding-right: 40px; padding-top: 4px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="center" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-style: italic; font-weight: normal; line-height: 18px;">NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT (coagulation Factor VIIa, recombinant) is indicated for: Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets, and treatment of bleeding episodes and perioperative management in adults with acquired hemophilia</td> </tr> </table> </td> </tr> </table> </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" style="background-color: #f3f3f4;"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <th width="30" style="width: 30px;" class="mobile-hide"> </th> <th align="center" valign="top" class="col-290 responsive-th" style="font-weight: normal; width: 290px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" valign="top" class="text-center" style="padding-bottom: 12px; padding-top: 8px;"><img src="https://emails.hemo.novo.cglife.dev/emails/n7-hcp-pharmacy-cpd/images/badge-graphic.png" width="190" height="140" border="0" alt="Image of 35+ years badge" style="display: inline-block;"></td> </tr> <tr> <td align="left" valign="top" class="email-gutter-mobile-only text-center mfs-24 mlh-32" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 26px; font-weight: bold; line-height: 34px; padding-bottom: 12px; padding-left: 0; padding-right: 0;">#1 prescribed bypassing agent in hospitals<sup style="font-size: 60%; line-height: 1;">3,c</sup></td> </tr> <tr> <td align="left" valign="top" class="email-gutter-mobile-only text-center mfs-16 mlh-22" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 18px; font-weight: normal; line-height: 24px; padding-bottom: 20px; padding-left: 0; padding-right: 0;">AND the only rFVIIa approved for surgery in children and adults.<sup style="font-size: 70%; line-height: 1;">1,d</sup></td> </tr> <tr> <td align="left" valign="top" class="email-gutter-mobile-only mpb-24" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 14px; padding-left: 0; padding-right: 0;"> <sup style="font-size: 70%; line-height: 1;">a</sup>Administer as a slow bolus injection over 2 to 5 minutes, depending on the dose administered.<sup style="font-size: 70%; line-height: 1;">1</sup><br> <sup style="font-size: 70%; line-height: 1;">b</sup>Compassionate use, also known as expanded access, began enrolling in 1988; FDA approval for hemophilia A or B with inhibitors received in 1999.<br> <sup style="font-size: 70%; line-height: 1;">c</sup>Based on Acumetis data collected Q4 2024 through Q4 2025.<sup style="font-size: 70%; line-height: 1;">3</sup><br> <sup style="font-size: 70%; line-height: 1;">d</sup>Perioperative management in acquired hemophilia is indicated for adults only. </td> </tr> </table> </th> <th width="15" style="width: 15px;" class="mobile-hide"> </th> <th align="center" valign="top" class="col-335 responsive-th" style="font-weight: normal; width: 335px;"> <img src="https://emails.hemo.novo.cglife.dev/emails/n7-hcp-pharmacy-cpd/images/main-image-desktop.jpg" width="335" height="516" border="0" alt class="mobile-hide" style="display: block;"> <!--[if !mso]><!--> <div class="mobile-only-content" style="display: none; max-height: 0; max-width: 0; visibility: hidden; width: 0;"> <img src="https://emails.hemo.novo.cglife.dev/emails/n7-hcp-pharmacy-cpd/images/main-image-mobile.jpg" width="750" height="640" border="0" alt class="img-responsive" style="display: block; max-width: 750px;"> </div> <!--<![endif]--> </th> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter" style="background-color: #001965; padding-bottom: 36px; padding-left: 30px; padding-right: 30px; padding-top: 40px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" class="email-gutter-desktop-only-20" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 20px; font-weight: normal; line-height: 28px; padding-bottom: 24px; padding-left: 20px; padding-right: 20px;">NovoSeven<sup style="font-size: 60%; line-height: 1;">®</sup> RT has been proven effective for bleed resolution and surgery across 5 indications—more than any other rFVIIa product<sup style="font-size: 60%; line-height: 1;">1,4</sup></td> </tr> <tr> <td align="center" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 20px; font-weight: bold; line-height: 28px; padding-bottom: 32px;">CHAwI | CHBwI | Acquired hemophilia | GT with refractoriness to platelets | CFVIId</td> </tr> <tr> <td align="center" class="text-center" style="padding-bottom: 32px;"> <a href="https://www.novomedlink.com/rare-bleeding-disorders/products/treatments/novosevenrt/hospital-use/overview.html" target="_blank" style="background-color: #ff0000; border-radius: 44px; color: #ffffff; display: inline-block; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: bold; line-height: 20px; mso-padding-alt: 0; padding-bottom: 12px; padding-left: 30px; padding-right: 30px; padding-top: 12px; text-decoration: none; text-underline-color: #ff0000;"><!--[if mso]><i style="mso-font-width:150%; mso-text-raise:140%;" hidden> </i><span style="mso-text-raise:70%;"><![endif]-->Why NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT<!--[if mso]></span><i style="mso-font-width:150%;" hidden> ​</i><![endif]--></a> </td> </tr> <tr> <td align="left" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 14px;">CFVIId=congenital factor VII deficiency; CHAwI=congenital hemophilia A with inhibitors; CHBwI=congenital hemophilia B with inhibitors; GT=Glanzmann’s thrombasthenia; rFVIIa=recombinant factor VIIa.</td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter mpb-20" style="padding-bottom: 36px; padding-left: 30px; padding-right: 30px; padding-top: 32px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 24px; font-weight: normal; line-height: 28px; padding-bottom: 36px;"><b>4 reasons</b> your hospital can count on NovoSeven<sup style="font-size: 60%; line-height: 1;">®</sup> RT</td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" valign="top" width="70" style="width: 70px;"><img src="https://emails.hemo.novo.cglife.dev/emails/n7-hcp-pharmacy-cpd/images/icon-efficacy.png" width="50" height="50" border="0" alt="Icon" style="display: block;"></td> <td align="left" valign="top"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: bold; line-height: 18px; padding-bottom: 4px;">Efficacy</td> </tr> <tr> <td align="left" class="mpb-44" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 18px; padding-bottom: 24px;">Proven efficacy for bleed resolution and surgery across 5 indications—more than any other bypassing agent.<sup style="font-size: 70%; line-height: 1;">1,4-6</sup></td> </tr> </table> </td> </tr> <tr> <td align="left" valign="top" width="70" style="width: 70px;"><img src="https://emails.hemo.novo.cglife.dev/emails/n7-hcp-pharmacy-cpd/images/icon-utilization.png" width="50" height="50" border="0" alt="Icon" style="display: block;"></td> <td align="left" valign="top"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: bold; line-height: 18px; padding-bottom: 4px;">Predictable utilization</td> </tr> <tr> <td align="left" class="mpb-44" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 18px; padding-bottom: 24px;">NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT has one dosing regimen for patients with CHwI regardless of bleed severity. That consistent dosing may lead to predictable utilization.<sup style="font-size: 70%; line-height: 1;">1</sup></td> </tr> </table> </td> </tr> <tr> <td align="left" valign="top" width="70" style="padding-bottom: 24px; width: 70px;"><img src="https://emails.hemo.novo.cglife.dev/emails/n7-hcp-pharmacy-cpd/images/icon-speed.png" width="50" height="50" border="0" alt="Icon" style="display: block;"></td> <td align="left" valign="top"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: bold; line-height: 18px; padding-bottom: 4px;">Speed</td> </tr> <tr> <td align="left" class="mpb-44" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 18px; padding-bottom: 24px;">Faster to infuse compared with FEIBA<sup style="font-size: 70%; line-height: 1;">®</sup> and Obizur<sup style="font-size: 70%; line-height: 1;">®</sup>.<sup style="font-size: 70%; line-height: 1;">1,5,6,e</sup></td> </tr> </table> </td> </tr> <tr> <td align="left" valign="top" width="70" style="width: 70px;"><img src="https://emails.hemo.novo.cglife.dev/emails/n7-hcp-pharmacy-cpd/images/icon-safety-profile.png" width="50" height="50" border="0" alt="Icon" style="display: block;"></td> <td align="left" valign="top"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: bold; line-height: 18px; padding-bottom: 4px;">Safety profile</td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 18px; padding-bottom: 2px;">Low rate of thrombotic adverse events based on clinical trials and registry data.<sup style="font-size: 70%; line-height: 1;">1</sup></td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" valign="top" width="20" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: bold; line-height: 20px; width: 20px;">•</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: bold; line-height: 18px;">Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance. Thrombotic adverse reactions in pivotal clinical trials occurred in 0.2% of bleeding episodes in CHwI, 4% in AH, 0.8% in CFVIId, and <0.2% in GT with refractoriness to platelets.<sup style="font-size: 70%; line-height: 1;">1</sup></td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 14px; padding-bottom: 8px; padding-top: 40px;"><sup style="font-size: 70%; line-height: 1;">e</sup>Administer NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT as a slow bolus injection over 2 to 5 minutes, depending on the dose administered.<sup style="font-size: 70%; line-height: 1;">1</sup> FEIBA<sup style="font-size: 70%; line-height: 1;">®</sup> should be injected or infused intravenously at a rate that does not exceed 10 units per kg of body weight per minute. For a dose of 75 U/kg, this equates to an infusion time of at least 7.5 minutes per kg of body weight.<sup style="font-size: 70%; line-height: 1;">5</sup> Administer Obizur<sup style="font-size: 70%; line-height: 1;">®</sup> intravenously at a rate of 1 to 2 mL per minute. For a 75-kg patient receiving a dose of 200 U/kg, this corresponds to an infusion time of 15 to 30 minutes.<sup style="font-size: 70%; line-height: 1;">6</sup></td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 14px;">AH=acquired hemophilia, CHwI=congenital hemophilia with inhibitors</td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter" style="padding-bottom: 16px; padding-left: 30px; padding-right: 30px; padding-top: 12px;"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="center" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 20px; padding-bottom: 12px;">Scroll to see how NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT continues to support your patients.</td> </tr> <tr> <td align="center"><img src="https://emails.hemo.novo.cglife.dev/emails/n7-hcp-pharmacy-cpd/images/arrow.png" width="50" height="30" border="0" alt style="display: block;"></td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter" style="padding-bottom: 20px; padding-left: 30px; padding-right: 30px; padding-top: 20px;"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="center"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 22px; font-weight: normal; line-height: 1.3; padding-bottom: 15px;"> Important Safety Information</td> </tr> <tr> <td align="center" style="padding: 2px; background-color: #001965;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" style="border: 2px solid #ffffff; background-color: #ffffff;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" style="background-color: #ffffff; padding-bottom: 20px; padding-left: 14px; padding-right: 14px; padding-top: 20px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" class="mpb-15" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 19px; padding-bottom: 10px;">WARNING: THROMBOSIS</td> </tr> <tr> <td align="left"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 19px;"> Serious arterial and venous thrombotic events following administration of NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT have been reported </td> </tr> </table> </td> </tr> <tr> <td align="left"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 19px;"> Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT </td> </tr> </table> </td> </tr> <tr> <td align="left"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 19px;"> Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis </td> </tr> </table> </td> </tr> </table> </td> </tr> </table> </td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 20px; padding-bottom: 15px; padding-top: 25px;">Warnings and Precautions</td> </tr> <tr> <td align="left"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"> Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance </td> </tr> </table> </td> </tr> <tr> <td align="left" style="padding-bottom: 24px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"> Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events </td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 20px; padding-bottom: 15px;">Please <a href="https://www.novomedlink.com/rare-bleeding-disorders/products/treatments/novosevenrt.html?showIsi=true" target="_blank" style="color: #ff0000; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">click here</a> or scroll below for additional Important Safety Information.</td> </tr> </table> </td> </tr> </table> </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter" style="background-color: #f3f3f4; padding-bottom: 32px; padding-left: 30px; padding-right: 30px; padding-top: 32px;"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 24px; font-weight: normal; line-height: 32px; padding-bottom: 24px;">NovoSeven<sup style="font-size: 60%; line-height: 1;">®</sup> RT for <b>acute and emergent bleeding</b> in the ER</td> </tr> <tr> <td align="center"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" class="email-gutter-40" style="background-color: #ffffff; padding-bottom: 12px; padding-left: 40px; padding-right: 40px; padding-top: 20px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" valign="top" width="20" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: bold; line-height: 20px; padding-bottom: 8px; width: 20px;">•</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 20px; padding-bottom: 8px;">For situations where patients have inhibitors, <b>MASAC recommends</b> that care should be urgently discussed with the patient’s hematologist. If in a life- or limb-threatening scenario, the safest immediate action is to prescribe rFVIIa at a dose of 90 mcg/kg or FEIBA<sup style="font-size: 70%; line-height: 1;">®</sup> at 75-100 units/kg.<sup style="font-size: 70%; line-height: 1;">7</sup></td> </tr> <tr> <td align="center" valign="top" width="20" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: bold; line-height: 20px; padding-bottom: 8px; width: 20px;">•</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 20px; padding-bottom: 8px;">For CHAwI patients on emicizumab, <b>MASAC recommends</b> rFVIIa first; avoid FEIBA<sup style="font-size: 70%; line-height: 1;">®</sup> (pd-aPCC) if possible.<sup style="font-size: 70%; line-height: 1;">8</sup></td> </tr> <tr> <td align="center" valign="top" width="20" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: bold; line-height: 20px; padding-bottom: 8px; width: 20px;">•</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 20px; padding-bottom: 8px;">If FEIBA<sup style="font-size: 70%; line-height: 1;">®</sup> is used in CHAwI patients on emicizumab, minimize duration; thrombosis and TMA may be associated with >24 hours usage above 100 units/kg/day.<sup style="font-size: 70%; line-height: 1;">8</sup></td> </tr> </table> </td> </tr> </table> </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter" style="padding-bottom: 36px; padding-left: 30px; padding-right: 30px; padding-top: 32px;"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 24px; font-weight: bold; line-height: 32px; padding-bottom: 44px;">Efficient for your hospital pharmacy</td> </tr> </table> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <th align="center" valign="top" class="col-290 responsive-th mpb-32" style="font-weight: normal; width: 290px;"><img src="https://emails.hemo.novo.cglife.dev/emails/n7-hcp-pharmacy-cpd/images/box-image.png" width="270" height="200" border="0" alt="Image of NovoSeven® RT box" style="display: block;"></th> <th width="25" style="width: 25px;" class="mobile-hide"> </th> <th align="center" valign="top" class="col-295 responsive-th" style="font-weight: normal; width: 295px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" valign="top" width="20" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 20px; padding-bottom: 8px; width: 20px;">•</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 20px; padding-bottom: 8px;">Low-volume dosing and compact packaging to help maximize space.<sup style="font-size: 70%; line-height: 1;">1</sup></td> </tr> <tr> <td align="center" valign="top" width="20" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 20px; padding-bottom: 8px; width: 20px;">•</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 20px; padding-bottom: 8px;">Room temperature storage up to 77 °F.<sup style="font-size: 70%; line-height: 1;">1,f</sup></td> </tr> <tr> <td align="center" valign="top" width="20" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 20px; padding-bottom: 8px; width: 20px;">•</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 20px; padding-bottom: 8px;">The histidine diluent is provided in either a vial or prefilled diluent syringe.<sup style="font-size: 70%; line-height: 1;">1</sup></td> </tr> <tr> <td align="center" valign="top" width="20" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 20px; padding-bottom: 8px; width: 20px;">•</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 20px; padding-bottom: 8px;">Available in <span style="white-space: nowrap;">1-mg</span>, <span style="white-space: nowrap;">2-mg</span>, <span style="white-space: nowrap;">5-mg</span>, and <span style="white-space: nowrap;">8-mg</span> vials with everything needed for reconstitution in 1 box.<sup style="font-size: 70%; line-height: 1;">1</sup></td> </tr> </table> </th> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 14px; padding-top: 32px;"><sup style="font-size: 70%; line-height: 1;">f</sup>Prior to reconstitution, store NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT powder and histidine diluent between 36-77 °F. After reconstitution, store NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT either at room temperature or refrigerated for up to 3 hours. Do not freeze reconstituted NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT or store in syringes.<sup style="font-size: 70%; line-height: 1;">1</sup></td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter" style="background-color: #001965; padding-bottom: 40px; padding-left: 30px; padding-right: 30px; padding-top: 40px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" valign="top" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 20px; font-weight: normal; line-height: 26px; padding-bottom: 28px;">NovoSeven<sup style="font-size: 60%; line-height: 1;">®</sup> RT has been building on more than 35 years of rFVIIa experience.<sup style="font-size: 60%; line-height: 1;">1,2</sup></td> </tr> <tr> <td align="center" class="text-center"> <a href="https://www.novomedlink.com/rare-bleeding-disorders/products/treatments/novosevenrt/hospital-use/overview.html" target="_blank" style="background-color: #ff0000; border-radius: 44px; color: #ffffff; display: inline-block; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: bold; line-height: 20px; mso-padding-alt: 0; padding-bottom: 12px; padding-left: 30px; padding-right: 30px; padding-top: 12px; text-decoration: none; text-underline-color: #ff0000;"><!--[if mso]><i style="mso-font-width:150%; mso-text-raise:140%;" hidden> </i><span style="mso-text-raise:70%;"><![endif]-->Learn more<!--[if mso]></span><i style="mso-font-width:150%;" hidden> ​</i><![endif]--></a> </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter" style="padding-bottom: 36px; padding-left: 30px; padding-right: 30px; padding-top: 32px;"><table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 22px; font-weight: normal; line-height: 1.3; padding-bottom: 15px;">Indications and Usage</td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px; padding-bottom: 15px;"> NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT (coagulation Factor VIIa, recombinant) is a coagulation factor indicated for: </td> </tr> <tr> <td align="left"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"> Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets </td> </tr> </table> </td> </tr> <tr> <td align="left" style="padding-bottom: 15px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"> Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia </td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 22px; font-weight: normal; line-height: 1.3; padding-bottom: 20px; padding-top: 10px;">Important Safety Information (cont’d)</td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 20px; padding-bottom: 15px;">Warnings and Precautions </td> </tr> <tr> <td align="left"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"> Hypersensitivity reactions, including anaphylaxis, can occur with NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur </td> </tr> </table> </td> </tr> <tr> <td align="left"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"> Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed </td> </tr> </table> </td> </tr> <tr> <td align="left" style="padding-bottom: 15px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"> Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis </td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 20px; padding-bottom: 15px;">Adverse Reactions</td> </tr> <tr> <td align="left" style="padding-bottom: 15px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"> The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia </td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 20px; padding-bottom: 15px;">Drug Interactions</td> </tr> <tr> <td align="left" style="padding-bottom: 24px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"> Thrombosis may occur if NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT is administered concomitantly with Coagulation Factor XIII </td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 20px; padding-bottom: 15px;">Please <a href="https://www.novo-pi.com/novosevenrt.pdf" target="_blank" style="color: #ff0000; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">click here</a> for Prescribing Information, including Boxed Warning.</td> </tr> </table> </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="left" class="email-gutter" style="padding-bottom: 12px; padding-left: 30px; padding-right: 30px;"> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tr> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 1.4; padding-bottom: 12px;"><b>References:</b></td> </tr> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tr> <td width="20" align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">1.</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;"><span class="default-blue-text">NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT [package insert]. Plainsboro, NJ; Novo Nordisk Inc.</span></td> </tr> <tr> <td width="20" align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">2.</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;"><span class="default-blue-text">Hedner U. History of rFVIIa therapy. <i>Thromb Res</i>. 2010;125(suppl 1):54-56.</span></td> </tr> <tr> <td width="20" align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">3.</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;"><span class="default-blue-text">Data on file as of Q4 2025. Novo Nordisk Inc; Plainsboro, NJ.</span></td> </tr> <tr> <td width="20" align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">4.</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;"><span class="default-blue-text">SEVENFACT<sup style="font-size: 70%; line-height: 1;">®</sup> [package insert]. Louisville, KY: HEMA Biologics, LLC; 2025.</span></td> </tr> <tr> <td width="20" align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">5.</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;"><span class="default-blue-text">FEIBA<sup style="font-size: 70%; line-height: 1;">®</sup> [package insert]. Lexington, MA: Takeda Pharmaceuticals U.S.A., Inc; 2024.</span></td> </tr> <tr> <td width="20" align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">6.</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;"><span class="default-blue-text">Obizur<sup style="font-size: 70%; line-height: 1;">®</sup> [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2024.</span></td> </tr> <tr> <td width="20" align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">7.</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;"><span class="default-blue-text">National Bleeding Disorders Foundation. Guidelines for emergency department management of individuals with hemophilia and other bleeding disorders. MASAC document #257. Approved December 2, 2019. Adopted December 5, 2019. Accessed June 23, 2026. https://www.hemophilia.org/healthcare-professionals/guidelines-on-care/masac-documents/masac-document-257-guidelines-for-emergency-department-management-of-individuals-with-hemophilia-and-other-bleeding-disorders</span></td> </tr> <tr> <td width="20" align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">8.</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;"><span class="default-blue-text">MASAC recommendation on the use and management of emicizumab-kxwh (Hemlibra<sup style="font-size: 70%; line-height: 1;">®</sup>) for hemophilia A with and without inhibitors. MASAC Document #268. Accessed August 9, 2023. https://www.hemophilia.org/healthcare-professionals/guidelines-on-care/masac-documents/masac-document-268-recommendation-on-the-use-and-management-of-emicizumab-kxwh-hemlibrar-for-hemophilia-a-with-and-without-inhibitors</span></td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter" style="padding-bottom: 20px; padding-left: 30px; padding-right: 30px; padding-top: 20px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td valign="top"> <table cellpadding="0" cellspacing="0" border="0" width="100%" style="border-top: 1px solid #979797"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-style: italic; font-weight: bold; line-height: 22px; padding-bottom: 24px; padding-top: 24px;">Please click on the link to see WAC pricing for the product mentioned above: <a href="https://www.novopricing.com/novosevenrt.html" style="color: #025edc; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;" target="_blank">Product Pricing</a>.</td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;"><span class="default-blue-link-text">Please do not respond to this email. If you would like to contact us, please <a href="https://www.novonordisk-us.com/contact-us.html" target="_blank" style="color: #025edc; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">click here</a> or call <span class="default-blue-link-text" style="white-space: nowrap;">1-800-727-6500</span>.</span></td> </tr> </table> </td> </tr> <tr> <td valign="bottom" style="padding-bottom: 20px; padding-top: 20px;"> <table cellpadding="0" cellspacing="0" border="0" align="left" width="100%"> <tr> <td align="left" valign="bottom" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 16px;"><span class="default-blue-text">NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> is a registered trademark of Novo Nordisk Health Care AG.<br>novoMEDLINK™ is a trademark of Novo Nordisk A/S.<br>Novo Nordisk is a registered trademark of Novo Nordisk A/S.<br>All other trademarks, registered or unregistered, are the property of their respective owners.<br>© 2026 Novo Nordisk All rights reserved. <span style="white-space: nowrap;">US26NSVN00014</span> <span style="white-space: nowrap;">July 2026</span></span></td> <td align="right" valign="bottom" class="col-80 mobile-hide" style="width: 80px;"><img src="https://emails.hemo.novo.cglife.dev/emails/n7-hcp-pharmacy-cpd/images/logo-novo-nordisk.png" width="75" height="55" alt="Novo Nordisk logo." style="display: block;"></td> </tr> </table> <!--[if !mso]><!--> <div class="mobile-only-content" style="display: none; max-height: 0; max-width: 0; visibility: hidden; width: 0;"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="center" valign="top" style="padding-top: 20px;"><img src="https://emails.hemo.novo.cglife.dev/emails/n7-hcp-pharmacy-cpd/images/logo-novo-nordisk.png" width="75" height="55" alt="Novo Nordisk logo." style="display: block;"></td> </tr> </table> </div> <!--<![endif]--> </td> </tr> </table> </td> </tr> </table> </td> </tr> </table> </center> </body> </html>